



Universiteit  
Leiden  
The Netherlands

## **Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease**

Coughlan, G.; Zhukovsky, P.; Puthusseryppady, V.; Gillings, R.; Minihane, A.M.; Cameron, D.; Hornberger, M.

### **Citation**


Coughlan, G., Zhukovsky, P., Puthusseryppady, V., Gillings, R., Minihane, A. M., Cameron, D., & Hornberger, M. (2020). Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease. *Neurobiology Of Aging*, 90, 110-118. doi:10.1016/j.neurobiolaging.2020.02.007

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4094631>

**Note:** To cite this publication please use the final published version (if applicable).



# Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease



Gillian Coughlan<sup>a</sup>, Peter Zhukovsky<sup>b</sup>, Vaisakh Puthusseryppady<sup>a</sup>, Rachel Gillings<sup>a</sup>, Anne-Marie Minihane<sup>a</sup>, Donnie Cameron<sup>a</sup>, Michael Hornberger<sup>a,\*</sup>

<sup>a</sup> Norwich Medical School, University of East Anglia, Norwich, UK

<sup>b</sup> Department of Psychology and Department of Psychiatry, University of Cambridge, Cambridge, UK

## ARTICLE INFO

### Article history:

Received 27 October 2019

Received in revised form 10 February 2020

Accepted 10 February 2020

Available online 19 February 2020

### Keywords:

Spatial navigation

Path integration

Preclinical Alzheimer's disease

APOE genotype

Functional connectivity

## ABSTRACT

Navigation processes that are selectively mediated by functional activity in the entorhinal cortex may be a marker of preclinical Alzheimer's disease (AD). Here, we tested if a short path integration paradigm can detect the strongest genetic-risk phenotype of AD in large sample of apolipoprotein E (APOE)-genotyped individuals. We also examined the associations between APOE-mediated navigation process, subjective cognitive decline, and rest-stating network connectivity. Navigation discrepancies classified 77% the APOE-genotyped cohort into their respective low-risk  $\epsilon 3\epsilon 3$  and high-risk  $\epsilon 3\epsilon 4$  categories. When connectivity strength between entorhinal and the posterior cingulate cortices (also a functional correlate of strongest APOE-dependant behavioral characteristics) was considered, this classification accuracy increased to 85%. Our findings present a whole picture of at-genetic-risk AD, including select impairment in path integration, self-report cognitive decline, and altered network activity that is reminiscent of the pathological spread of preclinical AD disease. These findings may have important implications for the early detection of AD.

© 2020 Elsevier Inc. All rights reserved.

## 1. Introduction

Late-onset Alzheimer's disease (AD) is one of the biggest burdens to modern society with up to 50 million people living with the disease worldwide and no curative therapies to treat the underlying cause of the disease pathology (Nichols et al., 2019). As current evidence shows that gold standard episodic memory tests fail to capture the first symptomatic manifestation of AD (Coughlan et al., 2018b; Jessen et al., 2014; Zimmermann and Butler, 2018; Zimmermann et al., 2019), alternative diagnostic tools are urgently required to advance cognitive diagnostics for incipient AD. Spatial orientation is a promising preclinical marker and is already established as a critical diagnostic tool in the late clinical and early prodromal stages of disease (Hort et al., 2007, 2014; Howett et al., 2019; Laczó et al., 2009; Lester et al., 2017; Mokrisova et al., 2016; Pai and Jacobs, 2004; Serino and Riva, 2013; Tu et al., 2015; Vlček and Laczó, 2014). For example, spatial navigation tasks, such as the Virtual Supermarket Test (VST) (Tu et al., 2015), distinguish AD

from other dementias and have been implemented in high-profile clinical trials because of their high sensitivity and specificity of AD pathophysiology (Ritchie et al., 2016; Ritchie and Ritchie, 2012).

Patients with AD typically sustain widespread navigation deficits, with severe difficulty storing and retrieving an allocentric representation (or a cognitive map) of the environment (DePoloyi et al., 2007; Jheng and Pai, 2009; Serino et al., 2015). This is due to significant neuronal loss in the hippocampus where place cells are located and mediate the human and rodent cognitive map (Bird and Burgess, 2008; O'Keefe and Nadel, 1978). Patients with AD also experience loss of egocentric self-reference navigation strategy because of abnormal structural and cellular changes in the retrosplenial cortex, the posterior cingulate cortex (PCC), and parietal cortex of the brain (Mokrisova et al., 2016; Pai and Yang, 2013; Pengas et al., 2010; Serino et al., 2015). More recent developments in immersive virtual reality path integration (or self-motion) tests show that even individuals in the earlier stage of the disease spectrum characterized by "mild cognitive impairment", suffer significant navigational errors during path integration, which has been directly associated with volumetric loss in the entorhinal cortex (EC) (Howett et al., 2019). This is important, because in the earlier asymptomatic stage of disease known as "preclinical AD", neuropathology is relatively localized to the EC,

\* Corresponding author at: Norwich Medical School, Bob Champion Research and Education Building, University of East Anglia, James Watson Road, Norwich NR4 7TJ, UK. Tel.: +441603597139; fax: +441603593752.

E-mail address: [m.hornberger@uea.ac.uk](mailto:m.hornberger@uea.ac.uk) (M. Hornberger).

suggesting that path integration tests may be sensitive to subtle preclinical changes in navigation performance (Jack et al., 2018; Sperling et al., 2011). On a cellular level, reduced grid cell representations in the EC correlate path integration deficits in healthy at-genetic-risk apolipoprotein E (APOE)  $\epsilon 4$  carriers, who are 3 to 4 times more likely to develop AD compared with non- $\epsilon 4$  carriers (Corder et al., 1993; Kunz et al., 2015). The same pattern of navigational discrepancies was replicated on the Sea Hero Quest game, which was then shown to discriminate  $\epsilon 4$  carriers from noncarriers with a classification accuracy of 72%, although no MRI data were available to pinpoint the neural changes that gave rise to  $\epsilon 4$ -related path integration deficits (Coughlan et al., 2019). Adding further support to the hypothesis that EC-mediated navigation changes may represent an early cognitive marker for preclinical AD, transgenic rodent models show spatial memory deficits measured on the Morris water maze occur just before mature tau tangles spread beyond the EC (Fu et al., 2017). Although the field is largely focused on EC-mediated navigation impairments for the early detection of preclinical AD, functional connectivity (FC) changes also occur in other brain regions such as the PCC and the precuneus (Badhwar et al., 2017; Hanseeuw et al., 2017; Minoshima et al., 1997; Pengas et al., 2010; Sperling et al., 2011). These more partial based changes are understood to be functional responses to early AD pathology within medial temporal lobe (Badhwar et al., 2017; Braak and Del Tredici, 2015; Chase, 2014). Despite this, resting-state FC within the spatial network that connects the EC, the PCC, and the precuneus have not yet been examined in the context of navigation impairments in preclinical AD. To address this gap, we examined navigation performance and resting-state FC in APOE-genotyped  $\epsilon 4$  carriers and noncarriers. We first tested 4 major navigation process using a short path integration paradigm called the VST, and then examined the relationship between navigation performance and FC in a subset of the study sample; with a specific focus on the connectivity strength between the EC, the hippocampus, the PCC, and the precuneus. We hypothesized that if  $\epsilon 4$  navigation impairment was captured on the path integration test, impairment would correlate with reduced edge strength of the EC in the proposed neural network. As an additional measure, we assessed if subjective cognitive impairment, often considered a first symptomatic manifestation of disease (Jessen et al., 2014), accompanies navigation impairment and/or altered connectivity strength in the neural network.

## 2. Materials and methods

### 2.1. Participants

We recruited 150 participants between 50 and 75 years to participate in a research study at the University of East Anglia. Written consent was obtained from all participants and ethical approval was obtained from Faculty of Medicine and Health Sciences Ethics Committee at the University of East Anglia, Reference FMH/2016/2017–11. All 150 participants were prescreened over the phone for exclusion criteria including psychiatric or neurological disease, substance dependence disorder and clinical depression and/or anxiety. Individuals with medicated cholesterol or blood pressure were included in the study, but medication intake was recorded to ensure there were not differences between genetic groups. Moreover, only participants with normal or corrected-to-normal vision were retained because of the nature of the VR task. Family history of AD was not included in the analysis, as there was considerable uncertainty when participants were asked the number of parents (0, 1, or 2) with dementia and in particular the type of dementia. Finally, saliva samples were collected via buccal swab from participants who passed this screening and their APOE

genotype status was determined. Please refer to the study by Coughlan et al. (2019) for a description on the APOE genotyping method used on the study cohort.


All identified APOE  $\epsilon 4$  allele carriers who represent 25% of the population (23% APOE  $\epsilon 3\epsilon 4$ , 2% APOE  $\epsilon 4\epsilon 4$ ; Corbo and Scacchi, 1999; Liu et al., 2013) were matched with a subset of the  $\epsilon 3\epsilon 3$  carriers, which is the population wild-type genotype (60%) for age and sex (see Table S1 for group background characteristics). Homozygous APOE  $\epsilon 4$  carriers (2% of the population) and APOE  $\epsilon 2$  carriers (13% of the UK population) were excluded. This yielded a final sample size of 64 (including 32  $\epsilon 3\epsilon 3$  carriers and 32  $\epsilon 3\epsilon 4$  carriers) all of whom underwent cognitive testing. Mean age of the  $\epsilon 3\epsilon 3$  group and the  $\epsilon 3\epsilon 4$  group was  $62.28 \pm 6.04$  and  $62.19 \pm 6.64$ , respectively. Twenty  $\epsilon 3\epsilon 3$  carriers and 20  $\epsilon 3\epsilon 4$  carriers also underwent structural and functional MRI. One  $\epsilon 3\epsilon 3$  participant did not complete the scan because of distress and their data were excluded from the analysis. Two additional participants (2  $\epsilon 3\epsilon 4$  carriers) who completed the MRI stage of the study were removed because of a software error that led to severe artifacts in the resting-state fMRI data. After these exclusions, MRI data on 37 of 64 (58%) sample size was used for analysis, reaching an acceptable fMRI sample size (Pajula and Tohka, 2016). Among the genetic groups who underwent neuroimaging the mean age of the  $\epsilon 3\epsilon 3$  group was  $63.21 \pm 5.23$  (including 11 male 8 females) and the mean age of the  $\epsilon 3\epsilon 4$  group was  $62.01 \pm 6.92$  (including 8 male 10 females). Please see supplementary information (SI) Fig. 1 for a summary of the sample size breakdown across study stages.

### 2.2. Paradigm overview

The VST is a sensitive and specific measure for differentiating AD from other dementia types (Coughlan et al., 2018a; Tu et al., 2015, 2017). It includes a path integration test and measures (1) egocentric orientation, (2) short-term spatial memory, (3) heading direction, and (4) central (vs. boundary) based navigation preferences. In brief, an iPad 9.7 (Apple Inc) is used to show participants 7–14-second video clips of a moving shopping trolley in a virtual reality supermarket from the first-person perspective (Fig. 1A–C). The absence of landmarks in the supermarket aims to ensure the test taps into EC-grid cell dependent strategies rather than striatal-mediated landmark-based navigation. Once the video clip stops, participants indicate in real life the direction of their starting point (egocentric orientation; Fig. 1D). In a second step, participants indicate their finishing location (short-term spatial memory; Fig. 1E) and heading direction on a VST map (gray arrow). We extended our VST paradigm to a fourth spatial measure based on evidence of an entorhinal-mediated bias or tendency to navigate toward environmental boundaries during path integration in at-genetic-risk AD. Specifically, we recorded the number of responses in the center and boundary space of the supermarket map to produce a central navigation preference measure (Fig. 1F; see supplementary text for more information on the creation of the central navigation preference measure).

### 2.3. Neuropsychological assessment

The aim of the present study was to assess the impact of APOE genotype independent of, and before, AD symptomology. The Addenbrooke's cognitive examination (ACE-III) was used to detect cognitive impairment associated with AD (Matias-Guiu et al., 2017). Only participants who scored in the normal range (ACE-III > 88) were retained. The Rey–Osterrieth complex figure test (RCFT; with 3-min delayed recall) and the Four Mountains test were used as secondary screening measures to assess any nonverbal episodic memory or spatial memory differences between genetic groups (Chan et al., 2016; Shin et al., 2006).



**Fig. 1.** Spatial orientation was assessed using an ecological virtual supermarket environment. (A) The layout of the virtual environment did not include any notable landmarks. (B) An iPad 9.7 (Apple Inc, etc) was used to show participants 7- to 14-s video clips of a moving shopping trolley. All trials began at the same location in the supermarket but followed different routes to reach a different end point in each trial. Videos were presented from a first-person perspective and participants were taken to a set location while making a series of 90-degree turn. (C) Once the video clip stopped, (D) participants indicate the real-life direction of their starting point. (E) Immediately following, participants indicate their finishing location (short-term spatial memory) and heading direction on a VST map. (F) Number of place responses made in the center space and boundary spaces were recorded. Abbreviations: VST, virtual supermarket task.

#### 2.4. Subjective cognitive change assessment

Subjective cognitive decline was assessed to identify decline in self-perceived episodic memory and executive function over the 5 years before testing. In previous work, subjective memory concerns have been identified in asymptomatic familial AD carriers, and concerns are seemingly predictive of faster rates of memory decline (Samieri et al., 2014; Weston et al., 2018). The presence of subjective cognitive concerns is also related to abnormal changes in A $\beta$  and tau biomarkers in APOE  $\epsilon$ 4 carriers (Risacher et al., 2015) and is thus considered important for early detection. Here, we measure this using the Cognitive Change Index (CCI; Rattanabannakit et al., 2016) that consists of 20 questions relating to the perceived decline. Responses are given on a 5-point scale ranging from 1 = “normal ability” to 5 = “severe problem”, with higher scores indicating larger concerns.

#### 2.5. Functional MRI acquisition

Structural and functional MRI data for 40 participants (20  $\epsilon$ 3 $\epsilon$ 3 carriers and 20  $\epsilon$ 3 $\epsilon$ 4 carriers) was obtained using a 3 tesla Discovery 750w wide bore system (GE Healthcare, Milwaukee, WI, USA) with a 12-channel phased-array head coil for signal reception. After localizers, T1-weighted (T1w) structural data were acquired using a whole-head 3D inversion-recovery fast spoiled gradient recalled echo sequence with the following parameters: repetition time = 7.7 ms; echo time = 3.1 ms; inversion time = 400 ms; field-of-view = 256 mm; acquired matrix = 256  $\times$  256; 200 sagittal sections of 1 mm thickness; flip angle = 11°; and an ASSET acceleration factor of 2 in the phase-encoding direction. Furthermore, a 3D T<sub>2</sub>-

weighted fluid attenuated inversion recovery (T<sub>2</sub>w FLAIR) sequence was prescribed as follows: repetition time = 4800 ms; echo time = 129 ms; inversion time = 1462 ms; field-of-view = 256 mm; acquired matrix = 256  $\times$  256; 182 sagittal sections of 1 mm thickness; flip angle = 90°; an ARC acceleration factor of 2 in the phase-encoding direction; and a “HyperSense” compressed sensing sub-sampling factor of 2.

Functional images were acquired using a gradient echo echo-planar imaging sequence with the following parameters: repetition time = 3500 ms; echo time = 30 ms; field-of-view = 240 mm; acquired matrix = 96  $\times$  96, reconstructed to 128  $\times$  128; 42 axial slices of 3.5 mm thickness; flip angle = 80°; and an ASSET acceleration factor of 2 in the phase-encoding direction. The fMRI time series consisted of 200 images, and the total acquisition time was 11 minutes 54 seconds. During functional runs, subjects were required to not fall asleep and keep alert with their eyes closed for 10 minutes. To avoid the effect of participants employing specific strategies to maintain alertness (e.g., reminiscing or counting scan number), participants were instructed not to think about anything in particular. Before analyses, all participant scans were visually inspected for significant head movements and artifacts. Please see [supplementary information](#) for preprocessing structural and functional MR images.

#### 2.6. Statistical analysis

Statistical analysis was performed using SPSS (v25.0), FSL (v6.0.0), MATLAB (MathWorks, R2018a), Octave (v4.4.1), and FreeSurfer for SI ROI morphometry analysis (v11.4.2).

**Table 1**  
Primary demographic and neuropsychological profile

	$\epsilon 3\epsilon 3$ carrier (n=32)	$\epsilon 3\epsilon 4$ carrier (n=32)	p value
Age (y)			
Mean (SD)	62.24 (5.32)	62.19 (5.58)	–
Sex			
Male	17	22	–
Female	15	10	–
ACE	94.47 (3.83)	92.88 (3.78)	0.12 (F = 2.49)
FMT	10.22 (2.91)	9.47 (1.23)	0.49 (F = 0.484)
ROCT			
Recall	22.92 (2.77)	17.66 (4.95)	0.06 (F = 2.061)
Copy	33.77 (6.36)	32.12 (2.67)	0.57 (F = 1.287)

Primary demographic and neuropsychological characteristics of the genetic groups (Independent sample *t*-test, 2-tailed).

Recall administered 3 min after copy.

Key: ACE, Addenbrooke's cognitive examination; FMT, 4 mountains test; ROCT, The Rey–Osterrieth complex figure.

An ANCOVA adjusted for age and sex was used to examine APOE differences on the neuropsychological assessment. Pearson's  $\chi^2$  assessed differences on secondary characteristics between APOE groups including, marital status, educational attainment, occupation, and medically controlled cholesterol and blood pressure. All group comparisons on VST spatial performance and CCI were conducted using the same general linear model including APOE, as main predictor of interest. Despite recruiting age- and sex-matched groups, we included age and sex as covariates given their strong effect on brain function and volume, navigation performance, and vulnerability to AD (Coutrot et al., 2018; Ferretti et al., 2018; Lester et al., 2017; Neu et al., 2017). We thus aimed to exclude any variance in the outcome measures that could be explained by these variables to determine an unbiased effect of APOE. Associations between VST and CCI measured were tested using partial Pearson correlation in SPSS adjusted for age and sex.

Voxel-based morphometry was conducted on whole-brain T<sub>1</sub>-weighted scans, using the voxel-based morphometry toolbox in FSL to confirm no gray matter structural differences between the genetic groups (Douaud et al., 2007; Good et al., 2001). FreeSurfer was used to segment and parcellate whole-brain T<sub>1</sub>-weighted images and generate volumetric measures for anatomical ROIs. FC between pairs of the 6 ROIs were analyzed by extracting the first eigenvector from the BOLD time series for each ROI, and each single participant, using “fslmeans”. If 2 brain regions show similarities in their BOLD time series, they are functionally connected (Haneef et al., 2014). A total of 195 of the 200 functional time points for each ROI were retained for analysis. All functional network modeling with time course data was carried out using FSLNets v0.6 so that the FC results were familywise error (FWE) corrected for multiple comparisons. After computing the subject-specific  $6^{\text{nodes}} \times 6^{\text{nodes}}$  connectivity matrix, direct and ridge regularized partial correlations were calculated between all pairs of ROIs, where direct correlations are correlations between 2 ROIs, controlling for the effect of all other ROI-ROI correlations. The

resulting Pearson correlation coefficients were converted to z scores via Fisher's transformation to test the significance of any FC differences between the genetic groups (Smith et al., 2011). All functional analyses were carried out in MNI standard space. Significance testing for functional MRI differences was conducted using voxel-wise general linear modeling by using the threshold-free cluster enhancement (TFCE) method. The TFCE produces voxel-wise *p*-values via 5000 permutation-based nonparametric testing (Nichols and Holmes, 2001). All scripts ran in the aforementioned software packages are available from authors.


### 3. Results

#### 3.1. Neuropsychological assessment

As expected, no differences between the 2 genetic groups were evident on the neuropsychological assessment (Table 1) or on secondary characteristics (see SI Table 1), which confirmed that the impact of APOE genotype before clinically detectable MCI/AD symptomatology could be measured.

#### 3.2. Spatial navigation assessment

Heading direction ( $F = 0.799$ ,  $p = 0.375$ , SI Fig. 1B) and short-term spatial memory ( $F = 0.014$ ,  $p = 0.907$ ) were unaffected by genotype, and thus, we concluded group differences on other VST submeasures could not be accounted for by differences in short-term spatial memory ability. Egocentric orientation was significantly different between genetic groups, with  $\epsilon 3\epsilon 4$  participants making fewer correct responses, compared with  $\epsilon 3\epsilon 3$  participants ( $F = 4.21$ ;  $p = 0.042$ ). Central navigation preference was also significantly different between the groups ( $F = 12.45$ ,  $p < 0.005$ ), with  $\epsilon 3\epsilon 3$  participants favoring more central responses and  $\epsilon 3\epsilon 4$  carriers favoring more boundary responses (see Fig. 2A–C; Table 2 for mean values).



**Fig. 2.** (A) The effect of genotype on short-term spatial memory, (B) egocentric orientation, and (C) central navigation preference.

\* Denotes significant effect of APOE genotype.

**Table 2**  
Effect of genotype on the VST spatial orientation paradigm

Variable	Mean (SD)	F	p value
Egocentric orientation			
$\epsilon 3\epsilon 3$	12.01 (2.3)	4.21	0.042
$\epsilon 3\epsilon 4$	10.94 (3.7)		
Heading direction			
$\epsilon 3\epsilon 3$	11.92 (2.7)	0.799	0.375
$\epsilon 3\epsilon 4$	11.31 (3.0)		
Spatial memory			
$\epsilon 3\epsilon 3$	7.43 (2.7)	0.014	0.907
$\epsilon 3\epsilon 4$	7.34 (3.0)		
Central vs. boundary preference			
$\epsilon 3\epsilon 3$	0.57 (0.21)	12.45	<0.005
$\epsilon 3\epsilon 4$	0.38 (0.14)		

ANCOVA with age and sex as covariates testing the difference of egocentric orientation, heading orientation, short-term spatial memory and central navigation preference.

Key: VST, virtual supermarket task.


### 3.3. Subjective cognitive change assessment

Next, we examined the significance of any differences on self-reported cognitive decline (within the last 5 years) between the genetic groups.  $\epsilon 3\epsilon 3$  participants reported less decline on both episodic memory ( $F = 5.24$ ,  $p = 0.026$ ) and executive function ( $F = 5.92$ ,  $p = 0.018$ ; SI Fig. 1D–E). Thus, we then sought to test associations between navigation performance on the VST and CCI scores. Heading orientation, short-term spatial memory and central navigation preference were not significantly associated with CCI scores. Egocentric orientation was associated with self-reported decline in executive function ( $r = -0.347$ ,  $p = 0.008$ ; i.e., better egocentric performance is related to less subjective decline).

### 3.4. Volumetric and/or functional connectivity


Having clarified the behavioral characteristics of  $\epsilon 4$ -related navigation impairment on the VST, we sought to investigate (1) the statistical significance of volumetric differences and/or FC changes between genetic groups and (2) if a neural correlate(s) for  $\epsilon 4$ -related navigation impairment on the VST could be identified. No significant gray matter volumetric differences between the groups ( $p = 0.18$ ) were present. As a secondary measure, we tested the mean ROI network volumes (right/left hippocampus, right/left EC, PCC, precuneus; see Fig. 3A). No difference was found between the genetic groups (see SI Table 2 for mean ROI volumetric values between groups).

Next, we examined FC between the ROIs to investigate potential differences in connectivity strength between the genetic groups. Full and partial correlations were tested in FSLNets to correct for multiple comparisons, meaning only effects withstanding familywise error correction were reported as significant. Right EC and PCC FC was significantly lower in  $\epsilon 3\epsilon 4$ s relative to  $\epsilon 3\epsilon 3$ s ( $t = -2.608$ ; uncorrected  $p = 0.01$ ; corrected  $p = 0.03$ ; 95% CI  $[-0.426 -0.053]$ ;  $r_s = 0.171$ ,  $F = 6.80$ ,  $p = 0.098$ ), even after multiple comparison correction ( $P_{FWE} = 0.027$ ) at a partial level (i.e., not controlling for all other ROI-ROI correlations). When controlling for all other ROI-ROI correlations (i.e., direct), the effect of APOE on right EC and PCC FC was significant at the uncorrected ( $p = 0.017$ ), but not at the corrected level ( $P_{FWE} = 0.157$ ). Trend differences in the opposite direction were observed between the precuneus and the PCC, with higher FC between these regions in  $\epsilon 3\epsilon 4$ s compared with  $\epsilon 3\epsilon 3$ s ( $t = -2.225$ ; uncorrected  $p = 0.03$ ; corrected  $p = 0.06$ ; 95% CI  $[0.009 0.214]$ ;  $r_s =$



**Fig. 3.** (A) APOE-dependent correlations in functional connectivity between selected ROIs: right/left hippocampus, right/left EC, PCC, precuneus. (B) The 6node  $\times$  6node network matrix of correlation coefficients represents connectivity strength between nodal pairs in a dual regression to test 2-group subject difference on subject specific nodal pair connectivity. Right EC and PCC connectivity was significantly lower in the  $\epsilon 3\epsilon 4$  group than in the  $\epsilon 3\epsilon 3$  group. Trend differences in the opposite direction were observed between the precuneus and the PCC, with higher functional connectivity between these regions the  $\epsilon 3\epsilon 4$  group than in the  $\epsilon 3\epsilon 3$  group. (C) Significant association between the right entorhinal and posterior cingulate cortices connectivity and i) central navigation preference ii) cognitive change index–episodic memory but not iii) cognitive change index–executive function. Abbreviations: APOE, apolipoprotein E; EC, entorhinal cortex; PCC, posterior cingulate cortex.

\* Denotes significant effect of APOE genotype.



**Fig. 4.** Logistic regression and ROC curves for right EC-PCC functional connectivity strength (green line) and VST cognitive measures central preference (blue) and egocentric orientation (red) predicting variants of the APOE genotype. (A) Logistic regression indicated that the regression model based on function connectivity and VST cognitive predictors was statistically significant. (B) Area under the curve (AUC) values indicated EC-PCC and egocentric orientation had a similar level of diagnostic accuracy, while central preference had the best accuracy of the 3 predictors. Abbreviations: APOE, apolipoprotein E; EC, entorhinal cortex; PCC, posterior cingulate cortex; VST, virtual supermarket task. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

0.228;  $p = 0.35$ ; Fig. 3B for group comparison connectivity matrix). Finally, to localize PCC connectivity differences in the EC, we used dual regression to test PCC connectivity in the whole brain which revealed reduced connectivity was localized to the dorsomedial subregion of the right EC (MNI [x y z] coordinates, [24 –6 –32], t<sub>FC</sub> corrected  $p < 0.05$ ). Please see [supplementary information](#) for the independent  $\epsilon 3\epsilon 3$  and  $\epsilon 3\epsilon 4$  connectivity matrices (SI Fig. 2).

### 3.5. Functional connectivity and $\epsilon 4$ -sensitive navigation processes

Having determined altered FC changes in the EC, PCC, and precuneus between genetic groups, FC strength between each ROI pair was correlated with the  $\epsilon 4$ -sensitive VST measures: egocentric orientation and central navigation preference. We expected that right-EC-PCC FC would correlate with at least one of the  $\epsilon 4$ -related behavioral characteristics. Right EC-PCC connectivity strength negatively correlated with central navigation preference ( $t = 2.45$ ,  $r = 0.40$ , corrected  $P_{FWE} = 0.018$ ) when direct (but not partial) correlations were used as a connectivity metric (Fig. 3C). No correlate in the predefined neural network for egocentric orientation was present. See [supplementary information](#) for investigations on the functional neural correlates of the 2 additional VST measures.

### 3.6. $\epsilon 4$ -related functional connectivity and subjective cognitive decline

Based on the  $\epsilon 4$ -related changes on self-reported cognitive decline, we then measured associations between EC-PCC FC with CCI scores. Connectivity strength between the right EC-PCC was

negatively correlated with subjective decline in episodic memory ( $t = -3.01$ ,  $r = -0.407$ , uncorrected  $p = 0.005$ , corrected  $P_{FWE} = 0.017$ ), but not with executive function ( $t = -2.02$ ,  $r = -0.341$ , uncorrected  $p = 0.052$ ; Fig. 3C).

### 3.7. Classifying genetic groups based on VST and functional connectivity

Although no neurofunctional correlate was identified for egocentric orientation or subjective executive function decline, the neurofunctional correlate of the 2 strongest  $\epsilon 4$  behavioral characteristics, central navigation preference and subjective episodic memory decline, overlapped. Thus, as a final step, we tested its clinical utility to classify at-genetic-risk AD. In the first instance, we did not include FC and subjective decline measures, as our primary aim was to test the diagnostic value of the VST for at-genetic-risk AD. Thus, the first logistic regression model entered aimed to classify  $\epsilon 3\epsilon 3$  and  $\epsilon 3\epsilon 4$  carriers based on central navigation preference and egocentric orientation measure. This model was statistically significant ( $\chi^2(2) 20.22$ ,  $p < 0.001$ ) and correctly classified 77.4% of the overall cohort ( $n = 64$ ). The percentage of classification was equal across  $\epsilon 4$  carriers and noncarriers. We then included the right EC-PCC measure to weigh the utility of including a neurofunctional correlate to improve the classification. Note the sample size dropped to 37 with the inclusion of MRI measures. As expected, the regression model was statistically significant,  $\chi^2(3) 16.85$ ,  $p < 0.001$ ) and classification accuracy shifted from 77.4% to 85%. Specifically, the model correctly classified 82.3% of  $\epsilon 3\epsilon 3$  carriers and 88.3% of the  $\epsilon 3\epsilon 4$  carriers (Fig. 4A). The log odds units presented are the values for the logistic regression equation for predicting APOE status from the 3 independent variables. The prediction equation is

$$\log\left(\frac{p}{1-p}\right) = 6.86 - 7.33 * \text{central navigation preference} - .28 * \text{egocentric orientation} - 1.47 * [\text{right EC} - \text{PCC}]$$

ROC curves were computed with these 3 predictors. Area under the curve (AUC) values indicated right EC-PCC connectivity (AUC 0.702, SE 0.092) and the egocentric task (AUC 0.659, SE 0.098) had a similar level of diagnostic accuracy. Central navigation preference showed the best accuracy of the 3 predictors (AUC 0.810, SE 0.073; Fig. 4 B).

#### 4. Discussion

APOE  $\epsilon$ 4 is the strongest genetic risk factor for late-onset AD. Yet, whether preclinical stage cognitive changes are detectable on a short clinically feasible task is unknown. Our results show that the classification accuracy of the path integration test, coupled with intrinsic FC strength between the EC-PCC reaches 85% providing a springboard for the development of a simple multimodal framework for at-genetic-risk AD. Extending the existing literature, we show that (1) navigation discrepancies following path integration co-exist with subjective cognitive concern in adults at-genetic risk of AD and (2) reduced network connectivity between the right EC and the PCC correlates with navigation discrepancies and subjective episodic memory concerns which characterize the at-genetic-risk behavioral phenotype.

Significant differences between the APOE genetic groups were found in 2 of 4 of the VST spatial submeasures: Egocentric orientation and central navigation preference. Egocentric orientation requires participants to form an accurate representation of the supermarket environment during self-motion and then integrate this representation at the finishing location to produce an accurate directional representation of the starting point.  $\epsilon$ 4 carriers demonstrated significantly more difficulty identifying their starting point, suggesting  $\epsilon$ 4-related problems integrating allocentric-egocentric frames. Although short-term forgetting could explain this effect, the  $\epsilon$ 4 group showed no impairments on the spatial memory control measures, compared with the noncarrier group (i.e., the VST short-term spatial memory task and the 4 mountains task), making a memory-based causation unlikely. The central navigation preference adopted for this study measures the number of allocentric location responses in the center versus the boundary area of the virtual supermarket following path integration. This measure then provides a means of dissociating between central versus the boundary responses preferences (or biases). The most striking  $\epsilon$ 4 behavioral discrepancy appeared here as  $\epsilon$ 4 carriers exhibited a strong response biases toward the boundary, compared with noncarriers.

Behaviorally, the  $\epsilon$ 4-related bias for reduced central navigation preferences is consistent with entorhinal-mediated navigation pattern changes during path integration observed on 2 other experimental navigation tasks (Kunz et al., 2015; please see Hardcastle et al., 2015 for discussion on border-cell mediated error correction in response to dysfunctional grid-cell activity in the EC). This is the first time  $\epsilon$ 4-related border biases were found following path integration; however, and although no neural FC correlate emerged for  $\epsilon$ 4-related egocentric orientation deficit, reduced FC between the right EC-PCC emerged as a significant neural substrate for border preferences in the at-genetic-risk group. Right EC-PCC FC also predicted the degree of episodic memory decline, as reported on the CCI (see Contreras et al., 2017 for more information on the CCI).

To the best of our knowledge, this is the first study to show APOE  $\epsilon$ 4 carriers with self-assessed episodic memory and executive function decline also show navigation discrepancies, and that border navigation preferences and perceived episodic memory decline are mediated to be the FC strength of neural pathways between the EC and PCC. Considering that subjective episodic memory decline is believed to be predictive of early A $\beta$

accumulation (Contreras et al., 2017; Jessen et al., 2014; Mulder et al., 2010) and coincides subtle navigation deficits as shown here, we conclude that subjective complaints may well contribute to a more sensitive and specific diagnosis of preclinical AD, although the relevance of subjective concerns for clinical practice is outside the boundaries of this study.

The role of reduced EC-PCC FC in preclinical may not be surprising, as typically intracellular tau projects from the EC and surrounding areas, to the PCC in the first stages of disease (Belloy et al., 2019; Hanseeuw et al., 2019; Jacobs et al., 2018), consistent with animal models that show in amyloid positive rodents, tau pathology propagation begins in the EC before spreading to the parietal cortex (Ahmed et al., 2014; Khan et al., 2013). This pattern of projection may explain the reduced FC in the at-genetic-risk group, and potentially the impeded translation of the allocentric or egocentric coordination systems, given that the allocentric system relies on entorhinal-hippocampal axis and the egocentric system relies on parietal/PCC regions. In opposition of this theory, the egocentric orientation measure did not correlate with the FC strength between the EC and PCC or any other ROI-ROI correlates. It may be that egocentric orientation changes are underpinned by functional changes between regions not examined, for example, in prefrontal lobe areas where extracellular deposition of A $\beta$  plaques are also found early in disease (Braak and Del Tredici, 2015). This is certainly possible, given the shared variance between egocentric orientation ability and frontal lobe-mediated executive function measured on the CCI, which was found here and elsewhere (Moffat et al., 2007). Finally, increased PCC-precuneus connectivity in the genetic-risk group was also found and may be understood in the context of animal models that demonstrate moderate levels of A $\beta$  in the brain can enhance FC due to compensatory brain mechanisms. This explains why increased connectivity strength in intrinsic brain networks is commonly found in  $\epsilon$ 4 cohorts (Badhwar et al., 2017; Chase, 2014; Machulda et al., 2011).

Despite our results largely supporting and extending current theories of preclinical AD models, the study has limitations. First, the sample size fell from 64 to 37 when investigating the neural correlates of  $\epsilon$ 4-related navigation impairment, which prevents generalization. We also cannot rule out the possibility that boundary-driven navigation behavioral is caused by another neural mechanism and/or the fact that boundary landmarks, although intentionally hidden in the VST, may exert an influence toward the border in the  $\epsilon$ 4 group. Of course, longitudinally tracking these participants to confirm whether multimodal framework presented here is predictive of future development of MCI or clinical AD is desired, but will take up to a decade to achieve. Moreover, as we cannot say if navigation changes precede subjective cognitive deficits or vice versa, this ought to be followed up in future investigations. Future studies should also consider using a PCC-mediated memory consolidation task in a similar cohort (such as that presented in Bird et al., 2015), to examine if this process is compromised in preclinical AD. This will add further insight into whether the field should consider PCC-mediated behavioral discrepancies as a marker for preclinical AD, as the current focus is primarily on EC-mediated tasks.

In conclusion, we have shown a distinct association between navigational deficits and altered FC in 3 key nodes of the spatial navigation network. Our results provide important insight into the navigational discrepancies sustained by the presence of  $\epsilon$ 4 genotype and the underlying neurofunctional entities that appear to be consistent with the topographical spread of preclinical disease from the EC to the PCC. As recent clinical trials of disease-modifying agents in Alzheimer's disease have failed (Sevigny et al., 2016), the addition of simple multimodal diagnostic models for at-risk AD should facilitate earlier and targeted intervention to those "at-risk".

This would allow neuroprotective compounds a higher opportunity of success, with intervention before macroscopic neuronal loss (Dubois et al., 2014; Reiman et al., 2015). Although further work is required to recommend VST as means of enrolling individuals in future clinical trials, the present study aims to stimulate the integration of navigational testing for consideration in upcoming pre-clinical AD-screening practices.

### Data availability

Link will be provided <https://osf.io>.

### Disclosure statement

The authors have no actual or potential conflicts of interest.

### CRediT authorship contribution statement

**Gillian Coughlan:** Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Validation, Writing - review & editing. **Peter Zhukovsky:** Visualization, Investigation, Software, Validation, Writing - review & editing. **Vaisakh Puthusserypady:** Writing - review & editing. **Rachel Gillings:** Data curation, Writing - original draft. **Anne-Marie Minihane:** Writing - review & editing. **Donnie Cameron:** Software, Validation. **Michael Hornberger:** Conceptualization, Methodology, Software, Data curation, Writing - original draft, Supervision, Writing - review & editing.

### Acknowledgements

The authors would like to thank Dr Sicong Tu who codeveloped the virtual supermarket test. They also wish to extend thanks to all participants who devoted their time to this research.

This research was funded by the Faculty of Medicine and Health Sciences, University of East Anglia, United Kingdom and by the Biotechnology and Biological Sciences Research Council UK.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.neurobiolaging.2020.02.007>.

### References

- Ahmed, Z., Cooper, J., Murray, T.K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M.A., Cavallini, A., Jackson, S., Bose, S., Clavaguera, F., Tolnay, M., Lavenir, I., Goedert, M., Hutton, M.L., O'Neill, M.J., 2014. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. *Acta Neuropathol.* 127, 667–683.
- Badhwar, A.P., Tam, A., Dansereau, C., Orban, P., Hoffstaedter, F., Bellec, P., 2017. Resting-state network dysfunction in Alzheimer's disease: a systematic review and meta-analysis. *Alzheimers Dement.* 8, 73–85.
- Belloy, M.E., Napolioni, V., Greicius, M.D., 2019. A Quarter Century of APOE and Alzheimer's disease: progress to date and the path forward. *Neuron* 101, 820–838.
- Bird, C.M., Burgess, N., 2008. The hippocampus and memory: insights from spatial processing. *Nat. Rev. Neurosci.* 9, 182–194.
- Bird, C.M., Keidel, J.L., Ing, L.P., Horner, A.J., Burgess, N., 2015. Consolidation of complex events via reinstatement in posterior cingulate cortex. *J. Neurosci.* 35, 14426–14434.
- Braak, H., Del Tredici, K., 2015. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. *Brain* 138, 2814–2833.
- Chan, D., Gallaher, L.M., Moodley, K., Minati, L., Burgess, N., Hartley, T., 2016. The 4 mountains test: a short test of spatial memory with high sensitivity for the diagnosis of pre-dementia alzheimer's disease. *J. Vis. Exp.* 54454. <https://doi.org/10.3791/54454>.
- Chase, A., 2014. Altered functional connectivity in preclinical dementia. *Nat. Rev. Neurosci.* 10, 609.
- Contreras, J.A., Goñi, J., Risacher, S.L., Amico, E., Yoder, K., Dzemidzic, M., West, J.D., McDonald, B.C., Farlow, M.R., Sporns, O., Saykin, A.J., 2017. Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered resting-state networks. *Alzheimers Dement.* 6, 40–49.
- Corbo, R.M., Scacchi, R., 1999. Apolipoprotein E (APOE) allele distribution in the world. Is APOE\*4 a "thrifty" allele? *Ann. Hum. Genet.* 63, 301–310.
- Corder, E., Saunders, A., Strittmatter, W., Schmechel, D., Gaskell, P., Small, G., Roses, A., Haines, J., Pericak-Vance, M., 1993. E type 4 allele gene dose of apolipoprotein and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Coughlan, G., Flanagan, E., Jeffs, S., Bertoux, M., Spiers, H., Mioshi, E., Hornberger, M., 2018a. Diagnostic relevance of spatial orientation for vascular dementia: a case study. *Dement. Neuropsychol.* 12, 85–91.
- Coughlan, G., Laczó, J., Hort, J., Minihane, A.-M., Hornberger, M., 2018b. Spatial navigation deficits — overlooked cognitive marker for preclinical Alzheimer disease? *Nat. Rev. Neurosci.* 14, 496–506.
- Coughlan, G., Coutrot, A., Khondoker, M., Minihane, A.-M., Spiers, H., Hornberger, M., 2019. Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer's disease. *Proc. Natl. Acad. Sci. U. S. A.* 116, 9285–9292.
- Coutrot, A., Silva, R., Manley, E., de Cothi, W., Sami, S., Bohbot, V.D., Wiener, J.M., Hölscher, C., Dalton, R.C., Hornberger, M., Spiers, H.J., 2018. Global determinants of navigation ability. *Curr. Biol.* 28, 2861–2866.e4.
- Delpolyi, A.R., Rankin, K.P., Mucke, L., Miller, B.L., Gorno-Tempini, M.L., 2007. Spatial cognition and the human navigation network in AD and MCI. *Neurology* 69, 986–997.
- Douaud, G., Smith, S., Jenkinson, M., Behrens, T., Johansen-Berg, H., Vickers, J., James, S., Voets, N., Watkins, K., Matthews, P.M., James, A., 2007. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. *Brain* 130, 2375–2386.
- Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., Dekosky, S.T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G.B., Fox, N.C., Galasko, D., Habert, M.O., Jicha, G.A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L.C., Vellas, B., Visser, P.J., Schneider, L., Stern, Y., Scheltens, P., Cummings, J.L., 2014. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol.* 13, 614–629.
- Ferretti, M., Iulita, M., Cavedo, E., Chiesa, P., Schumacher Dimech, A., Santuccion, A., Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depytere, H., Hampel, H., Women's Brain Project and the Alzheimer Precision Medicine Initiative, 2018. Sex differences in Alzheimer disease — the gateway to precision medicine. *Nat. Rev. Neurosci.* 14, 457–469.
- Fu, H., Rodriguez, G.A., Herman, M., Emrani, S., Nahmani, E., Barrett, G., Figueroa, H.Y., Goldberg, E., Hussaini, S.A., Duff, K.E., 2017. Tau pathology induces excitatory neuron loss, grid cell dysfunction, and spatial memory deficits reminiscent of early alzheimer's disease. *Neuron* 93, 533–541.e5.
- Good, C.D., Good, C.D., Johnsrude, I.S., Johnsrude, I.S., Ashburner, J., Ashburner, J., Henson, R.N., Henson, R.N., Friston, K.J., Friston, K.J., Frackowiak, R.S., Frackowiak, R.S., 2001. A voxel-based morphometric study of ageing in 465 normal adult human brains. *Neuroimage* 14, 21–36.
- Haneef, Z., Lenartowicz, A., Yeh, H.J., Engel, J., Stern, J.M., 2014. Network analysis of the default mode network using functional connectivity MRI in temporal lobe epilepsy. *J. Vis. Exp.* e51442.
- Hanseeuw, B.J., Betensky, R.A., Jacobs, H.L.L., Schultz, A.P., Sepulcre, J., Becker, J.A., Cosio, D.M.O., Farrell, M., Quiroz, Y.T., Mormino, E.C., Buckley, R.F., Papp, K.V., Amariglio, R.A., Dewachter, I., Ivanou, A., Huijbers, W., Hedden, T., Marshall, G.A., Chhatwal, J.P., Rentz, D.M., Sperling, R.A., Johnson, K., 2019. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. *JAMA Neurol.* 76, 986.
- Hanseeuw, B.J., Betensky, R.A., Schultz, A.P., Papp, K.V., Mormino, E.C., Sepulcre, J., Bark, J.S., Cosio, D.M., LaPoint, M., Chhatwal, J.P., Rentz, D.M., Sperling, R.A., Johnson, K.A., 2017. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. *Ann. Neurol.* 81, 583–596.
- Hardcastle, K., Ganguli, S., Giocomo, L.M., 2015. Environmental boundaries as an error correction mechanism for grid cells. *Neuron* 86, 827–839.
- Hort, J., Laczó, J., Vyhnálek, M., Bojar, M., Bureš, J., Vlček, K., 2007. Spatial navigation deficit in amnesic mild cognitive impairment. *Proc. Natl. Acad. Sci. U. S. A.* 104, 4042–4047.
- Hort, J., Andel, R., Mokrisova, I., Gazova, I., Amlerova, J., Valis, M., Coulson, E.J., Harrison, J., Windisch, M., Laczó, J., 2014. Effect of donepezil in alzheimer disease can be measured by a computerized human analog of the morris water maze. *Neurodegener. Dis.* 13, 192–196.
- Howett, D., Castegnar, A., Krzywicka, K., Hagman, J., Marchment, D., Henson, R., Rio, M., King, J.A., Burgess, N., Chan, D., 2019. Differentiation of mild cognitive impairment using an entorhinal cortex-based test of virtual reality navigation. *Brain* 142, 1751–1766.
- Jack, C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., Elliott, C., Masliah, E., Ryan, L., Silverberg, N., 2018. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 14, 535–562.
- Jacobs, H.L.L., Hedden, T., Schultz, A.P., Sepulcre, J., Perea, R.D., Amariglio, R.E., Papp, K.V., Rentz, D.M., Sperling, R.A., Johnson, K.A., 2018. Structural tract

- alterations predict down-stream tau accumulation in amyloid positive older individuals. *Nat. Neurosci.* 21, 424–431.
- Jessen, F., Amariglio, R.E., Van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K.A., Van Der Flier, W.M., Glodzik, L., Van Harten, A.C., De Leon, M.J., Mchugh, P., Mielke, M.M., Molinuevo, J.L., Mosconi, L., Osorio, R.S., Perrotin, A., Petersen, R.C., Rabin, L.A., Rami, L., Reisberg, B., Rentz, D.M., Sachdev, P.S., De La Sayette, V., Saykin, A.J., Scheltens, P., Shulman, M.B., Slavin, M.J., Sperling, R.A., Stewart, R., Uspenskaya, O., Vellas, B., Visser, P.J., Wagner, M., 2014. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease and Subjective Cognitive Decline Initiative (SCD-I) Working Group. *Alzheimers Dement.* 10, 844–852.
- Jheng, S.S., Pai, M.C., 2009. Cognitive map in patients with mild Alzheimer's disease: a computer-generated arena study. *Behav. Brain Res.* 200, 42–47.
- Khan, U.A., Liu, L., Provenzano, F.A., Berman, D.E., Profaci, C.P., Sloan, R., Mayeux, R., Duff, K.E., Small, S.A., 2013. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. *Nat. Neurosci.* 17, 304–311.
- Kunz, L., Schröder, T.N., Lee, H., Montag, C., Lachmann, B., Sariyska, R., Reuter, M., Stirnberg, R., Stöcker, T., Messing-Floeter, P.C., Fell, J., Doeller, C.F., Axmacher, N., 2015. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease supplementary materials. *Science* 350, 430–433.
- Laczó, J., Vlček, K., Vyhňálek, M., Vajnerová, O., Ort, M., Holmerová, I., Tolar, M., Andel, R., Bojar, M., Hort, J., 2009. Spatial navigation testing discriminates two types of amnesic mild cognitive impairment. *Behav. Brain Res.* 202, 252–259.
- Lester, A.W., Moffat, S.D., Wiener, J.M., Barnes, C.A., Wolbers, T., 2017. The aging navigational system. *Neuron* 95, 1019–1035.
- Liu, C.-C., Kanekiyo, T., Xu, H., Bu, G., 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat. Rev. Neurol.* 9, 106–118.
- Machulida, M.M., Jones, D.T., Vemuri, P., McDade, E., Avula, R., Przybelski, S., Boeve, B.F., Knopman, D.S., Petersen, R.C., Jack, C.R., 2011. Effect of APOE  $\epsilon$ 4 status on intrinsic network connectivity in cognitively normal elderly subjects. *Arch. Neurol.* 68, 1131–1136.
- Matias-Guiu, J.A., Cortés-Martínez, A., Valles-Salgado, M., Rognoni, T., Fernández-Matarrubia, M., Moreno-Ramos, T., Matías-Guiu, J., 2017. Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests. *Int. Psychogeriatr.* 29, 105–113.
- Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., Kuhl, D.E., 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann. Neurol.* 42, 85–94.
- Moffat, S.D., Kennedy, K.M., Rodrigue, K.M., Raz, N., 2007. Extrahippocampal contributions to age differences in human spatial navigation. *Cereb. Cortex.* 17, 1274–1282.
- Mokrisova, I., Laczó, J., Andel, R., Gazova, I., Vyhňálek, M., Nedelska, Z., Lvcik, D., Cerman, J., Vlček, K., Hort, J., 2016. Real-space path integration is impaired in Alzheimer's disease and mild cognitive impairment. *Behav. Brain Res.* 307, 150–158.
- Mulder, C., Verwey, N.A., Van Der Flier, W.M., Bouwman, F.H., Kok, A., Van Elk, E.J., Scheltens, P., Blankenstein, M.A., 2010. Amyloid- $\beta$ (1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. *Clin. Chem.* 56, 248–253.
- Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.S., Romero, K., Arneric, S.P., Redolfi, A., Orlandi, D., Frisoni, G.B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S.C., Kosciak, R., Wang, J.J., Hsu, W.C., Chen, Y.L., Toga, A.W., 2017. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. *JAMA Neurol.* 74, 1178–1189.
- Nichols, T.E., Holmes, A.P., 2001. Nonparametric permutation tests for functional neuroimaging: a primer with examples. *Hum. Brain Mapp.* 15, 1–25.
- Nichols, E., Szoeke, C.E.I., Vollset, S.E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M.T.E., Akinyemi, R.O., Alahdab, F., Asgedom, S.W., Awasthi, A., Barker-Collo, S.L., Baune, B.T., Béjot, Y., Belachew, A.B., Bennett, D.A., Biadgo, B., Bijani, A., Bin Sayeed, M.S., Brayne, C., Carpenter, D.O., Carvalho, F., Catalá-López, F., Cerin, E., Choi, J.Y.J., Dang, A.K., Degefa, M.G., Djalalinia, S., Dubey, M., Duken, E.E., Edvardsson, D., Endres, M., Eskandarieh, S., Faro, A., Farzadfar, F., Fereshtehnejad, S.M., Fernandes, E., Filip, I., Fischer, F., Gebre, A.K., Geremew, D., Ghasemi-Kasman, M., Gnedovskaya, E.V., Gupta, R., Hachinski, V., Hagos, T.B., Hamidi, S., Hankey, G.J., Haro, J.M., Hay, S.I., Irvani, S.S.N., Jha, R.P., Jonas, J.B., Kalani, R., Karch, A., Kasaeian, A., Khader, Y.S., Khalil, I.A., Khan, E.A., Khanna, T., Khoja, T.A.M., Khubchandani, J., Kisa, A., Kissimova-Skarbek, K., Kivimäki, M., Koyanagi, A., Krohn, K.J., Logroscino, G., Lorkowski, S., Majdan, M., Malekzadeh, R., März, W., Massano, J., Mengistu, G., Meretoja, A., Mohammadi, M., Mohammadi-Khanaposhtani, M., Mokdad, A.H., Mondello, S., Moradi, G., Nagel, G., Naghavi, M., Naik, G., Nguyen, L.H., Nguyen, T.H., Nirayo, Y.L., Nixon, M.R., Ofori-Assenso, R., Ogbo, F.A., Olagunju, A.T., Owolabi, M., Panda-Jonas, S., Passos, V.M.d.A., Pereira, D.M., Pinilla-Monsalve, G.D., Piradov, M.A., Pong, C.D., Poustchi, H., Qorbani, M., Radfar, A., Reiner, R.C., Robinson, S.R., Roshandel, G., Rostami, A., Russ, T.C., Sachdev, P.S., Safari, H., Safiri, S., Sahathevan, R., Salimi, Y., Satpathy, M., Sawhney, M., Saylan, M., Sepanlou, S.G., Shafieesabet, A., Shaikh, M.A., Sahraini, M.A., Shigematsu, M., Shiri, R., Shue, I., Silva, J.P., Smith, M., Sobhani, S., Stein, D.J., Tabarés-Seisdedos, R., Tovani-Palone, M.R., Tran, B.X., Tran, T.T., Tsegay, A.T., Ullah, I., Venketasubramanian, N., Vlassov, V., Wang, Y.P., Weiss, J., Westerman, R., Wijaratne, T., Wyper, G.M.A., Yano, Y., Yimer, E.M., Yonemoto, N., Youseffard, M., Zaidi, Z., Zare, Z., Vos, T., Feigin, V.L., Murray, C.J.L., 2019. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 18, 88–106.
- O'Keefe, John, Nadel, L., 1978. *The Hippocampus as a Cognitive Map*. Oxford University Press, Oxford, England.
- Pai, M.C., Jacobs, W.J., 2004. Topographical disorientation in community-residing patients with Alzheimer's disease. *Int. J. Geriatr. Psychiatry* 19, 250–255.
- Pai, M.-C., Yang, Y.-C., 2013. Impaired translation of spatial representation in young onset Alzheimer's disease patients. *Curr. Alzheimer Res.* 10, 95–103.
- Pajula, J., Tohka, J., 2016. How many is enough? Effect of sample size in inter-subject correlation analysis of fMRI. *Comput. Intell. Neurosci.* 2016, 2094601.
- Pengas, G., Hodges, J.R., Watson, P., Nestor, P.J., 2010. Focal posterior cingulate atrophy in incipient Alzheimer's disease. *Neurobiol. Aging* 31, 25–33.
- Rattanabannakit, C., Risacher, S.L., Gao, S., Lane, K.A., Brown, S.A., McDonald, B.C., Unverzagt, F.W., Apostolova, L.G., Saykin, A.J., Farlow, M.R., 2016. The cognitive change index as a measure of self and informant perception of cognitive decline: relation to neuropsychological tests. *J. Alzheimers Dis.* 51, 1145–1155.
- Reiman, E.M., Langbaum, J.B., Tariot, P.N., Lopera, F., Bateman, R.J., Morris, J.C., Sperling, R.A., Aisen, P.S., Roses, A.D., Welsh-Bohmer, K.A., Carrillo, M.C., Wengler, S., 2015. CAP—advancing the evaluation of preclinical Alzheimer disease treatments. *Nat. Rev. Neurol.* 12, 56–61.
- Risacher, S.L., Kim, S., Nho, K., Foroud, T., Shen, L., Petersen, R.C., Jack, C.R., Beckett, L.A., Aisen, P.S., Koeppe, R.A., Jagust, W.J., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., Saykin, A.J., Alzheimer's Disease Neuroimaging Initiative (ADNI), 2015. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. *Alzheimers Dement.* 11, 1417–1429.
- Ritchie, C.W., Ritchie, K., 2012. The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. *BMJ Open* 2, 1–6.
- Ritchie, C.W., Molinuevo, J.L., Truyen, L., Satlin, A., Van der Geyten, S., Lovestone, S., 2016. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. *Lancet Psychiatry* 3, 179–186.
- Samieri, C., Proust-Lima, C., M. Glymour, M., Okereke, O.I., Amariglio, R.E., Sperling, R.A., Rentz, D.M., Grodstein, F., 2014. Subjective cognitive concerns, episodic memory, and the APOE  $\epsilon$ 4 allele. *Alzheimers Dement.* 10, 752–759.e1.
- Serino, S., Riva, G., 2013. Getting lost in Alzheimer's disease: a break in the mental frame syncing. *Med. Hypotheses* 80, 416–421.
- Serino, S., Morganti, F., Di Stefano, F., Riva, G., 2015. Detecting early egocentric and allocentric impairments deficits in Alzheimer's disease: an experimental study with virtual reality. *Front. Aging Neurosci.* 7, 1–10.
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, paul H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M.S., Quintero-Monzon, O., Scannevin, R.H., Arnold, H.M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R.M., Sandrock, A., 2016. The antibody aducanumab reduces A $\beta$  plaques in Alzheimer's disease. *Nature* 537, 50–56.
- Shin, M.-S., Park, S.-Y., Park, S.-R., Seol, S.-H., Kwon, J.S., 2006. Clinical and empirical applications of the rey–Osterrieth complex figure test. *Nat. Protoc.* 1, 892–899.
- Smith, S.M., Miller, K.L., Salimi-khorshidi, G., Webster, M., Beckmann, C.F., Nichols, T.E., Ramsey, J.D., Woolrich, M.W., 2011. NeuroImage Network modeling methods for fMRI. *Neuroimage* 54, 875–891.
- Sperling, R.A., Aisen, P.S., Beckett, L.A., David, A., Bennett, S.C., 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging. *Alzheimers Dement.* 7, 280–292.
- Tu, S., Wong, S., Hodges, J.R., Irish, M., Piguot, O., Hornberger, M., 2015. Lost in spatial translation - a novel tool to objectively assess spatial disorientation in Alzheimer's disease and frontotemporal dementia. *Cortex* 67, 83–94.
- Tu, S., Spiers, H.J., Hodges, J.R., Piguot, O., Hornberger, M., 2017. Egocentric versus allocentric spatial memory in behavioral variant frontotemporal dementia and Alzheimer's disease. *J. Alzheimers Dis.* 59, 883–892.
- Vlček, K., Laczó, J., 2014. Neural correlates of spatial navigation changes in mild cognitive impairment and Alzheimer's disease. *Front. Behav. Neurosci.* 8, 89.
- Weston, P.S.J., Nicholas, J.M., Henley, S.M.D., Liang, Y., Macpherson, K., Donnachie, E., Schott, J.M., Rossor, M.N., Crutch, S.J., Butler, C.R., Zeman, A.Z., Fox, N.C., 2018. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. *Lancet Neurol.* 17, 117.
- Zimmermann, J.F., Butler, C.R., 2018. Accelerated long-term forgetting in asymptomatic APOE  $\epsilon$ 4 carriers. *Lancet Neurol.* 17, 394–395.
- Zimmermann, J., Alain, C., Butler, C., 2019. Impaired memory-guided attention in asymptomatic APOE4 carriers. *Sci. Rep.* 9, 1–15.